Karen Marie Walker sold $293k of KYTX
Chief Technology Officer at Kyverna Therapeutics, Inc.. 23,998 shares at an average of $12.20, traded Dec 15, 2025, filed Dec 17, 2025.
Score components
- +15RoleOfficer
- +14Trade size$293k at market
- +20Share of holdings soldSold 51% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +21.0%, 3m +23.6%, 6m +16.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-323332, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 15, 2025 | MOption exercise Common Stock10b5-1 | +23,998 | $4.83 | $116k | 46,634 | Dec 17, 2025 |
| Dec 15, 2025 | SOpen-market sale Common Stock10b5-1 | -23,998 | $12.20 | $293k | 22,636 | Dec 17, 2025 |
| Dec 15, 2025 | MOption exercise Stock option (right to buy)derivative10b5-1 | -23,998 | $0.00 | $0 | 85,865 | Dec 17, 2025 |
Related signals
Other insiders at Kyverna Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | Kyverna Therapeutics, Inc. | Westlake BioPartners Opportunity Fund I, L.P. owner | $1000k 133,333 shares | +18% | |
| 51Moderate | Kyverna Therapeutics, Inc. | Beth C Seidenberg director | $1000k 133,333 shares | +18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.